Improvement of Depression-Like Behavior and Memory Impairment with the Ethanol Extract of &lt;i&gt;Pleurotus eryngii&lt;/i&gt; in Ovariectomized Rats

Minami, Akira; Matsushita, Hiroshi; Horii, Yuuki; Ieno, Daisuke; Matsuda, Yukino; Saito, Masakazu; Kanazawa, Hiroaki; Ohyama, Yuriko; Wakatsuki, Akihiko; Takeda, Atsüshi; Hidari, Kazuya I.P.J.; Sabaratnam, Vikineswary; Suzuki, Takashi

doi:10.1248/bpb.b13-00657

Cited by 8 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are some researches related to estrogen-like drugs which improved neurological symptoms such as depression and memory impairment caused by surgical or natural menopause [36][37][38]. To determine whether the ethanol extracts of this Pleurotus eryngii (PEE) has estrogen-like activity, Minami et al [39] fed the extracts to the OVX rats and observed the immobility time of the OVX rats with the treatment of the extracts was significantly shortened during a forced swimming test. The Morris water maze test showed that spatial memory impairment in OVX rats was improved by PEE.…”

Section: Estrogen-like Activitymentioning

confidence: 99%

A Potent Pharmacological Mushroom: Pleurotus eryngii

Fu¹,

Liu²

2016

Fungal Genom Biol

View full text Add to dashboard Cite

Pleurotus eryngii, commonly known as the king oyster mushroom, has been used extensively in North Africa, Europe and Asia. A great deal of work has been carried out on therapeutic potential of Pleurotus eryngii. The edible Fungi perform multiple bioactivities: anticancer, antiviral, antioxidant, antimicrobial, anti-leukaemia, hypolipidemic, immuno-modulating and estrogen-like activity. These bioactive properties depend on its bioactive compounds such as polysaccharides, eryngiolide A, ubiquinone-9, pentacyclic triterpenoid and so on. The present review focuses on the potential pharmacological activities and provides reference for the study of Pleurotus eryngii in the future.

show abstract

Section: Estrogen-like Activitymentioning

confidence: 99%

A Potent Pharmacological Mushroom: Pleurotus eryngii

Fu¹,

Liu²

2016

Fungal Genom Biol

View full text Add to dashboard Cite

show abstract

“…The species used in all of the animal models were limited to rats and mice: we did not find instances of other rodent species that have been utilized as antidepressant screens ( Kramer et al, 1998 ; Alo et al, 2019 ). Fourteen of the studies used rats ( Matsuzaki et al, 2013 ; Minami et al, 2013 ; Tan et al, 2016 ; Liu C. et al, 2017 ; Song et al, 2017 ; Wang et al, 2017 ; Huang et al, 2020 ; Nascimento et al, 2020 ; Lin et al, 2021a ; Zhang L. et al, 2021 ; Lin et al, 2021b ; Anuar et al, 2022 ; Cheng, 2023 ; Rakoczy et al, 2023 ), while the remaining 36 studies used mice to test for antidepressant-like effects ( Zhou et al, 2005 ; Nishizawa et al, 2007 ; Koo et al, 2008 ; Singh et al, 2014 ; Tianzhu et al, 2014 ; Socala et al, 2015 ; Yao et al, 2015 ; Gupta et al, 2016 ; Huang et al, 2016 ; Nakamichi et al, 2016 ; Song et al, 2016 ; Xu, 2016 ; Bao et al, 2017 ; Liu Y. et al, 2017 ; Lin et al, 2017 ; Chiu et al, 2018 ; Mahmoudi et al, 2018 ; Ryu et al, 2018 ; Jin et al, 2019 ; Li et al, 2019 ; Song et al, 2020 ; Li H. et al, 2021 ; Li TJ. et al, 2021 ; Zhang T. et al, 2021 ; Chong et al, 2021 ; Hossen et al, 2021 ; Park et al, 2021 ; Singh et al, 2021 ; Zhao et al, 2021 ; Chou et al, 2022 ; Mi et al, 2022 ; Xin et al, 2022 ; Yu et al, 2022 ; Ezurike et al, 2023 ; Zhao et al, 2023 ; Hernandez-Leon et al, 2024 ).…”

Section: Resultsmentioning

confidence: 99%

A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity

Wang,

Kim,

Aleksandrova

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

One of the most important developments in psychopharmacology in the past decade has been the emergence of novel treatments for mood disorders, such as psilocybin for treatment-resistant depression. Psilocybin is most commonly found in different species of mushroom; however, the literature on mushroom and fungus extracts with potential antidepressant activity extends well beyond just psilocybin-containing mushrooms, and includes both psychedelic and non-psychedelic species. In the current review, we systematically review the preclinical literature on mushroom and fungus extracts, and their effects of animal models of depression and tests of antidepressant activity. The PICO structure, PRISMA checklist and the Cochrane Handbook for systematic reviews of intervention were used to guide the search strategy. A scoping search was conducted in electronic databases PubMed, CINAHL, Embase and Web of Science. The literature search identified 50 relevant and suitable published studies. These included 19 different species of mushrooms, as well as seven different species of other fungi. Nearly all studies reported antidepressant-like effects of treatment with extracts. Treatments were most commonly delivered orally, in both acute and chronically administered studies to predominantly male rodents. Multiple animal models of depression were used, the most common being unpredictable chronic mild stress, while the tail suspension test and forced swim test were most frequently used as standalone antidepressant screens. Details on each experiment with mushroom and fungus species are discussed in detail, while an evaluation is provided of the strengths and weaknesses of these studies.

show abstract

“…The Morris water maze test was performed as previously described [20]. Briefly, a transparent platform (10 cm in diameter) was submerged in a pool (130 cm in diameter) filled with water (22°C ± 2°C) and surrounded by a grey wall (57 cm in height) and two different objects.…”

Section: Methodsmentioning

confidence: 99%

Role of Sialidase in Long-Term Potentiation at Mossy Fiber-CA3 Synapses and Hippocampus-Dependent Spatial Memory

et al. 2016

Self Cite

View full text Add to dashboard Cite

Sialic acid bound to glycans in glycolipids and glycoproteins is essential for synaptic plasticity and memory. Sialidase (EC 3.2.1.18), which has 4 isozymes including Neu1, Neu2, Neu3 and Neu4, regulates the sialylation level of glycans by removing sialic acid from sialylglycoconjugate. In the present study, we investigated the distribution of sialidase activity in rat hippocampus and the role of sialidase in hippocampal memory processing. We previously developed a highly sensitive histochemical imaging probe for sialidase activity, BTP3-Neu5Ac. BTP3-Neu5Ac was cleaved efficiently by rat Neu2 and Neu4 at pH 7.3 and by Neu1 and Neu3 at pH 4.6. When a rat hippocampal acute slice was stained with BTP3-Neu5Ac at pH 7.3, mossy fiber terminal fields showed relatively intense sialidase activity. Thus, the role of sialidase in the synaptic plasticity was investigated at mossy fiber terminal fields. The long-term potentiation (LTP) at mossy fiber-CA3 pyramidal cell synapses was impaired by 2,3-dehydro-2-deoxy-N-acetylneuraminic acid (DANA), a sialidase inhibitor. DANA also failed to decrease paired-pulse facilitation after LTP induction. We also investigated the role of sialidase in hippocampus-dependent spatial memory by using the Morris water maze. The escape latency time to reach the platform was prolonged by DANA injection into the hippocampal CA3 region or by knockdown of Neu4 without affecting motility. The results show that the regulation of sialyl signaling by Neu4 is involved in hippocampal memory processing.

show abstract

Improvement of Depression-Like Behavior and Memory Impairment with the Ethanol Extract of <i>Pleurotus eryngii</i> in Ovariectomized Rats

Cited by 8 publications

References 45 publications

A Potent Pharmacological Mushroom: Pleurotus eryngii

A Potent Pharmacological Mushroom: Pleurotus eryngii

A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity

Role of Sialidase in Long-Term Potentiation at Mossy Fiber-CA3 Synapses and Hippocampus-Dependent Spatial Memory

Contact Info

Product

Resources

About